Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants

Nirsevimab is an extended half-life monoclonal antibody specific for the prefusion conformation of the respiratory syncytial virus (RSV) F protein, which has been studied in preterm and full-term infants in the phase 2b and phase 3 MELODY trials. We analyzed serum samples collected from 2,143 infant...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilkins, Deidre, Yuan, Yuan, Chang, Yue, Aksyuk, Anastasia A., Núñez, Beatriz Seoane, Wählby-Hamrén, Ulrika, Zhang, Tianhui, Abram, Michael E., Leach, Amanda, Villafana, Tonya, Esser, Mark T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10202809/
https://www.ncbi.nlm.nih.gov/pubmed/37095249
http://dx.doi.org/10.1038/s41591-023-02316-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10202809/
https://www.ncbi.nlm.nih.gov/pubmed/37095249
http://dx.doi.org/10.1038/s41591-023-02316-5

Ejemplares similares